Cancer
BRAF and MEK inhibitors
Targeted drugs for tumours with a BRAF V600 mutation, about half of melanomas: a BRAF inhibitor combined with a MEK inhibitor blocks the MAPK pathway at two points.
Mécanisme d’action
- BRAF V600E is a constantly active kinase that signals through MEK and ERK to drive proliferation.
- Vemurafenib, dabrafenib and encorafenib inhibit mutant BRAF; trametinib, cobimetinib and binimetinib inhibit MEK downstream.
- Combining them gives deeper responses and delays resistance; it also prevents the skin tumours that BRAF inhibitors alone provoke by paradoxically activating the pathway in normal cells.
Cibles moléculaires
- Mutant BRAF kinase: Inhibitor
- MEK1/2: Inhibitor
Médicaments : BRAF and MEK inhibitors
- Dabrafenib with trametinib
- Vemurafenib with cobimetinib
- Encorafenib with binimetinib
Indications thérapeutiques
- BRAF V600-mutant advanced melanoma, and after surgery for high-risk stage III
- BRAF-mutant lung cancer and colorectal cancer (encorafenib with an anti-EGFR antibody)
Maladies traitées
Effets indésirables
- Fever (dabrafenib)
- Photosensitivity and rash (vemurafenib)
- Cutaneous squamous cell carcinomas, mainly with a BRAF inhibitor alone
- Reduced ejection fraction and retinal problems (MEK inhibitors)
Contre-indications selon le terrain
- Heart failure (MEK inhibitors) (Avec précaution): They can reduce the ejection fraction.
- Pregnancy (Contre-indiqué): They harm the fetus.
- Long QT (Avec précaution): Vemurafenib prolongs the QT interval.
Autres précautions et interactions
- They are only for tumours with a BRAF V600 mutation; in BRAF wild-type tumours they can accelerate growth.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Kinase inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, BRAF & MEK inhibitors
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.